Cellectis SA share price logo

Cellectis SA

NASDAQ: CLLS

$1.11

+0.03

(+2.78%)

Live

as on

Cellectis SA Stock Performance

as on November 3, 2026 at 3:42 am IST

  • Day's Low

    $1.10
    $1.11
    downward going graph

    0.90%

    Downside

  • 52 Week's Low

    52 Week's High

    $0.88
    $5.45
    downward going graph

    20.65%

    Downside

    390.99%

    Upside

    downward going graph

Cellectis SA share price movements today

Previous Close
$1.08
Open
$1.10
Volume
13.6K
Market Cap
$108.8M
Day's Low - High
$1.10 - $1.11
52 Week Low - High
$0.88 - $5.45

Cellectis SA Historical Returns

1 Month Return
-24.48 %
3 Month Return
-60.73 %
1 Year Return
-68.7 %
3 Year Return
-64.12 %
5 Year Return
-91.44 %

Cellectis SA Stock Fundamentals & Key Indicators

Check Cellectis SA market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$108.8M

EPS (TTM)

-0.6641

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-1.78

Industry PE ratio

-3.03

PEG Ratio

0.02

EBITDA

-55.5M

Revenue (TTM)

56.6M

Profit Margin

74.68%

Return On Equity TTM

-94.14%

Cellectis SA vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Cellectis SA with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Cellectis SA image
Cellectis SA
Neutral$108.8M-91.44%-1.7874.68%0.00%
Moderna image
Moderna
Neutral$88.5B-36.40%-27.78-12.57%0.00%
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
StrongBuy$141.7B208.09%32.2786.04%0.00%
Regeneron image
Regeneron
Buy$95.5B45.26%19.7685.77%0.40%

Stock Returns calculator for Cellectis SA Stock including INR - Dollar returns

The Cellectis SA stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Cellectis SA investment value today

Current value as on today

₹34,414

Returns

-₹65,586

(-65.59%)

Returns from Cellectis SA Stock

-₹67,826 (-67.83%)

Dollar Impact

₹2,240 (+2.24%)

Analyst Recommendation on Cellectis SA Stock

Based on 1 analysts

HOLD

0.00%

Buy

100.00%

Hold

0.00%

Sell

Based on 1 analysts, 100% of analysts recommend a 'HOLD' rating for Cellectis SA. Average target price of $4.83

Cellectis SA Share Price Target

Get share price movements and forecasts by analysts on Cellectis SA.

What analysts predicted

77.02%UPSIDE

Target Price

$4.83

Current Price

$1.11

Analyzed by

1 Analysts

Target

$4.83

Cellectis SA target price $4.83, a slight upside of 77.02% compared to current price of $1.11. According to 1 analysts rating.

Indian Investors' Interest in Cellectis SA Stock

Search interest for Cellectis SA Stock has decreased by -68% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-68% versus previous 30 day period

Cellectis SA Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
4
8
16
12
10
16
35
10
5
5
Gross Profit
2
6
13
10
8
14
32
7
1
0
Operating Income
-20
-17
-10
-10
-14
-9
8
-17
-27
-25
EBITDA
11
-18
-16
14
-11
-16
7
-19
-22
-21
Interest Expense
1
1
2
1
1
2
2
2
2
2
Depreciation
4
4
4
5
4
5
5
5
4
4
Income Before Tax
5
-25
-23
6
-18
-23
0
-26
-19
-23
Income Tax Expense
0
0
0
0
0
0
-
0
-1
-1
Net Income
5
-25
-23
5
-18
-23
0
-26
-17
-21
Net Profit Margin
48.21%
81.02%
82.77%
80.22%
81.09%
85.50%
93.30%
71.15%
21.50%
15.62%

Cellectis SA Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
25
12
15
51
30
19
0
41
72
Gross Profit
22
9
3
49
28
10
-6
32
63
Operating Income
-92
-105
-123
-42
-103
-89
-97
-59
-33
EBITDA
-108
-93
-105
-43
-78
-76
-92
-9
-39
Interest Expense
0
0
2
3
4
3
5
7
8
Depreciation
3
2
6
7
14
18
18
19
20
Income Before Tax
-103
-88
-115
-53
-96
-98
-116
-36
-68
Income Tax Expense
-13
-
-
-
0
0
0
-
0
Net Income
-99
-78
-102
-81
-114
-106
-101
-36
-67
Net Profit Margin
89.60%
78.49%
25.00%
96.18%
93.92%
55.75%
-882.65%
77.88%
86.57%

Cellectis SA Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
5
-25
-23
5
-18
-23
0
-26
-17
-21
Operating Cash Flow
-23
52
-5
0
-17
-10
-1
-10
-15
-14
Investing Cash Flow
-2
-106
22
-16
4
-52
-3
22
-6
18
Financing Cash Flow
11
78
-4
2
-4
-4
-4
-4
-4
-3
Change in Cash
-13
26
10
-15
-15
-67
-7
9
-28
0

Cellectis SA Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-103
-88
-115
-53
-96
-98
-116
-36
-67
Operating Cash Flow
-52
-68
-69
-80
-104
-87
-24
22
-40
Investing Cash Flow
1
35
-35
-54
7
-2
-15
-102
-29
Financing Cash Flow
41
236
-3
27
47
1
82
89
-16
Change in Cash
1
195
-110
-99
-55
-92
43
6
-79

Global Institutional Holdings in Cellectis SA

Check out the Institutions with significant holdings in Cellectis SA.

Funds
Holdings
Delaware Group Equity Funds IV
0.94%
iShares
0.34%
Fidelity Concord Street Trust
0.00%
LoCorr Investment Trust
0.00%

Cellectis SA News & Key Events

  • img

    Today's Timeline - 15 September

    Tue, 03:55 PM

    -

    Wells Fargo reduced Cellectis price target to $3 from $4, keeping an Equal Weight rating as the company pivots to cardiometabolic opportunities.

    Tue, 04:30 PM

    -

    Baird lowered Cellectis price target to $8 from $10, maintaining an Outperform rating amid strategic pivot.

    Tue, 07:11 PM

    -

    Citizens downgraded Cellectis to Market Perform, halting allogeneic CAR T cell development and shifting focus to Talen-based genetic medicines.

Insights on Cellectis SA

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, CLLS stock has moved up by 11.7%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Moderna, Inc. Common Stock has given 211.3% return, outperforming this stock by 275.4%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 716.3% return, outperforming this stock by 785.0%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 4 quarters, 35.17M → 5.22M (in $), with an average decrease of 41.5% per quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, -17.82M → -21.78M (in $), with an average decrease of 22.2% per quarter

About Cellectis SA

Cellectis S.A. is a biotechnology firm in the clinical development stage, concentrating on the creation of immuno-oncology therapies. These therapies harness gene-edited T-cells engineered to express chimeric antigen receptors, designed to specifically identify and eliminate malignant cells. Its operations are divided into two distinct divisions: Therapeutics and Plants. The therapeutic pipeline includes several product candidates currently undergoing development. Among these is UCART19, an allogeneic T-cell therapy targeting CD19-expressing blood cancers such as acute lymphoblastic leukemia. Other key developments encompass ALLO-501 and ALLO-501A, designed for diffuse large B-cell lymphoma and follicular lymphoma in relapsed or refractory patients; ALLO-316, intended for Renal Cell Carcinoma; UCART123 for acute myeloid leukemia; and UCART22 for B-cell acute lymphoblastic leukemia. Furthermore, UCARTCS1 and ALLO-715 are being developed to combat multiple myeloma. Strategic partnerships form a crucial part of its operations, encompassing alliances with entities such as Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. The firm also maintains a dedicated research and development collaboration with Cytovia Therapeutics, Inc. Established in 1999, Cellectis S.A. maintains its principal offices in Paris, France.
OrganisationCellectis SA
Headquarters8, rue de la Croix Jarry, Paris, IF, 75013, FR
IndustryBiotechnology
CEOAndre Choulika

Key Management of Cellectis SA

Name

Title

Mr. Arthur Stril

CFO & Chief Business Officer

Ms. Marie-Bleuenn Terrier

General Counsel & Secretary of the Board of Directors

Ms. Kyung Nam-Wortman

Executive VP & Chief Human Resources Officer

Mr. Stephan Reynier M.Sc.

Chief Regulatory & Pharmaceutical Compliance Officer

Dr. Andre Choulika Ph.D.

Co-Founder, CEO & Director

Valerie Cros

Principal Financial Officer & Principal Accounting Officer

Mr. Jean Charles Epinat Ph.D.

Chief Technological Officer

Dr. Philippe Duchateau Ph.D.

Chief Scientific Officer

Pascalyne Wilson

Director of Communications

Dr. David J. Sourdive Ph.D.

Co-Founder, Deputy CEO, Executive VP of CMC & Manufacturing and Director

FAQs

What is Cellectis SA share price today?

Cellectis SA share price today is $1.11 as on . Cellectis SA share today touched a day high of $1.11 and a low of $1.10.

What is the 52 week high and 52 week low for Cellectis SA share?

Cellectis SA share touched a 52 week high of $5.45 on and a 52 week low of $0.88 on . Cellectis SA stock price today i.e. is trending at $1.11,which is 79.63% down from its 52 week high and 26.02% up from its 52 week low.

What is Cellectis SA's market capitalisation today?

Cellectis SA market capitalisation is $0.00T as on .

How to invest in Cellectis SA Stock (CLLS) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Cellectis SA on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Cellectis SA Stock (CLLS) from India?

Indian investors can start investing in Cellectis SA (CLLS) shares with as little as ₹94.9000015258789 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹949.00 in Cellectis SA stock (as per the Rupee-Dollar exchange rate as on ). Based on Cellectis SA share’s latest price of $1.11 as on November 2, 2026 at 10:12 pm IST, you will get 9.0090 shares of Cellectis SA. Learn more about fractional shares .

What are the returns that Cellectis SA has given to Indian investors in the last 5 years?

Cellectis SA stock has given -91.44% share price returns and 27.07% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?